Crossmark

Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Crossref DOI link: https://doi.org/10.1016/j.jacbts.2020.01.008

Published Print: 2020-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ståhle, Mia

Silvola, Johanna M.U.

Hellberg, Sanna

de Vries, Margreet

Quax, Paul H.A.

Kroon, Jeffrey

Rinne, Petteri

de Jong, Alwin

Liljenbäck, Heidi

Savisto, Nina

Wickman, Anna

Stroes, Erik S.G.

Ylä-Herttuala, Seppo

Saukko, Pekka

Abrahamsson, Tommy

Pettersson, Knut

Knuuti, Juhani

Roivainen, Anne

Saraste, Antti
Funding

Funding for this research was provided by:

Abbott Laboratories

Horizon 2020 (667837)

Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91619098)

AstraZeneca

Instrumentariumin Tiedesäätiö

Seventh Framework Programme

GE Healthcare

Turun Yliopistollinen Keskussairaala

Turun Yliopisto

Seventh Framework Programme (601728)

Sydäntutkimussäätiö

Sigrid Juséliuksen Säätiö

Suomen Kulttuurirahasto

Academy of Finland
License Information

Text and Data Mining valid from 2020-04-01

Text and Data Mining valid from 2020-04-01

Version of Record valid from 2020-01-21
More Information

This article is maintained by: Elsevier

Article Title: Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Journal Title: JACC: Basic to Translational Science

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jacbts.2020.01.008

Content Type: article

Copyright: © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.